NCT01327222

Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: IRCCS San Raffaele · Academic / Other
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.

Detailed description

There is no clear indication regarding the treatment of patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200. Treatment of eyes with low visual acuity could lead to a waste of resources, without any functional and social improvements. Aim of the present study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Bevacizumab	1.25 mg intravitreal bevacizumab

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2011-04-01
• Last updated: 2011-04-01

Locations

1 site across 1 country: Italy